A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies

Overview of attention for article published in Targeted Oncology, March 2017

Altmetric Badge

About this Attention Score

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 7,745 followers.

RT @ShaalanBeg: The first clinical trial protocol I wrote is published! @aacr @asco #Vailworkshop Great job team! Takes a village. https:/…

The first clinical trial protocol I wrote is published! @aacr @asco #Vailworkshop Great job team! Takes a village. https://t.co/E7xVvOUfkp

A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) with Everolimus in Advanced Solid Malignancies https://t.co/TzRTj7SSgf